Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beta lapachone

Drug Profile

Beta lapachone

Alternative Names: ARQ 501; BRN 0181499; CO-501; NSC 26326; NSC 629749; R 1668; SL 11001

Latest Information Update: 19 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dana-Farber Cancer Institute
  • Developer Merck & Co
  • Class Anti-inflammatories; Antifibrotics; Antineoplastics; Eye disorder therapies; Naphthoquinones; Obesity therapies; Small molecules
  • Mechanism of Action Apoptosis stimulants; E2F1 transcription factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Head and neck cancer; Leiomyoma; Pancreatic cancer; Solid tumours

Most Recent Events

  • 01 Apr 2022 Sumitomo Dainippon Pharma Oncology is now called Sumitomo Pharma Oncology
  • 01 Jul 2020 Boston Biomedical has merged with Tolero Pharmaceuticals to form Sumitomo Dainippon Pharma Oncology
  • 16 Jan 2020 ArQule has been acquired and merged into Merck & Co
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top